PFE - IPO Update: ALX Oncology Seeks $128 Million IPO
Quick Take
ALX Oncology (ALXO) intends to raise $128 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is developing treatment candidates for various blood and solid tumor cancer conditions.
ALXO is pursuing treatments in extremely large market spaces and has produced promising Phase 1b trial response results.
For life science investors with a patient hold time frame, the IPO is worth considering.
Company & Technology
Burlingame, California-based ALX was founded to advance a pipeline of drug treatments seeking to negate the